CSIMarket
 
Citius Oncology Inc  (NASDAQ: TENKU)
 

Citius Oncology Inc's Customers Performance

TENKU



 
TENKU's Source of Revenues During the corresponding time, Citius Oncology Inc sequentially revenue fell by -10.41 %. While revenue at the Citius Oncology Inc's corporate clients

• List of TENKU Customers




for the same period Citius Oncology Inc sequentially revenue fell by -10.41 %.

• List of TENKU Customers

Citius Oncology Inc's Business Units






Citius Oncology Inc's Comment on Sales, Marketing and Customers



The company serves customers in the United States and has established international distribution agreements for its product LYMPHIR in Greece, Cyprus, other Balkan countries, Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE through named patient programs. These programs provide access to LYMPHIR where permitted by local law but do not constitute commercial approval outside the United States. The company's commercial success depends on coverage and reimbursement by governmental authorities, private health insurers, and other third-party payers in the United States, the European Union, and other significant markets.





Citius Oncology Inc’s Comment on Sales, Marketing and Customers


The company serves customers in the United States and has established international distribution agreements for its product LYMPHIR in Greece, Cyprus, other Balkan countries, Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE through named patient programs. These programs provide access to LYMPHIR where permitted by local law but do not constitute commercial approval outside the United States. The company's commercial success depends on coverage and reimbursement by governmental authorities, private health insurers, and other third-party payers in the United States, the European Union, and other significant markets.








TENKU's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Citius Oncology Inc 4,747.18 0.00 -45.90 -
SUBTOTAL 0.00 0.00 0.00 -

Sources: Citius Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Citius Oncology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Citius Oncology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.